Clinical Trials

The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.

The purpose of this study is to determine if hydroxychloroquine is safe and effective for the prevention of a future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP).

The primary objective of this study is to determine the impact of ArthritisPower™ integration into the clinical evaluation of patients with RA on the primary endpoint of clinical improvement as defined by the continuous change in the Clinical Disease Activity Index.

Study objective: Define pharmacogenomics markers and clinical phenotype features associated with response to RA treatments. Using electronical medical records data and a blood draw with DNA for genotyping from prospectively recruited patients seen in rheumatology clinic (n=100), we will identify genomic markers and leading phenotype features of responders to routinely used anti-rheumatic medications at 3 and 6 months of treatment based on disease activity score with 28-joint count (DAS28), accounting for socioeconomic factors, comorbidities, RA characteristics and prior anti-rheumatic medication use. We hypothesize that: Patients responding to antirheumatic medication(s) and their combinations share similar phenotype and/or genomic markers.

The purpose of this study is to determine how best to monitor for flares in patients with rheumatoid arthritis (RA).

The purpose of this study is to understand how bacteria in the intestines  interact with the inflammation process in patients with rheumatoid arthritis.

The purpose of the study is to determine whether somatic mutations in T cells contribute to the pathogenesis of rheumatoid arthritis (RA).

Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor.

This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events of RoActemra/Actemra (tocilizumab) in comparison to etanercept in patients with rheumatoid arthritis. Patients will be randomized to receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks or 50 mg etane rcept subcutaneously weekly. The anticipated time on study drug is up to 5 years.

The purpose of this study is to explicate factors contributing to inadequate improvement in physical function and health-related quality of life despite appropriate disease-modifying treatment in persons with rheumatoid arthritis (RA) and inflammatory arthritis (IA) who meet 2010 ACR/EULAR classification criteria for RA. To do this, this study focuses on the contract of discordance, whereby the patient judges her/his disease to be either more or less active than the rheumatologist. The positive impact of this award is anticipated to be the development of a clinical framework and approach to managing the various causes of inadequate clinical improvement, ultimately improving patient-physician communication and ...

Objective: Identify a microbial biomarker signature that is predictive of treatment response in patients with rheumatoid arthritis (RA).

The overall objective of this study is to examine if the strategy starting of the addition of a tsDMARD, oral targeted molecule medications will lead to greater improvement in HAQ compared with the alternate approach of the addition of a non-TNF-biologic.

The purpose of this post-marketing study is to compare the safety of tofacitinib versus tumor necrosis factor inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers, when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and effectiveness parameters will be collected and evaluated in the study.

The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with anti-TNF-alpha agents.

The purpose of this study is to get synovial tissue from patients with rheumatoid arthritis by minimally invasive ultrasound guided biopsy, for the purpose of identifying the processes that are responsible for the cause of the disease. 

Rheumatoid arthritis (RA) patients have a higher prevalence of subclinical atherosclerosis than the general population. In addition, they experience higher rates of heart failure with preserved ejection fraction (HFpEF). There is evidence that myocardial mechanics and left ventricular diastolic function are more abnormal in the RA population and these changes occur earlier than in the general population. Recently a study suggested that RA patient have abnormal myocardial inflammation during a disease flare and that this is improved with anti-inflammatory treatment. Our study is aimed at describing the prevalence of myocardial inflammation in patients during active RA disease flares and comparing ...

The purpose of this study is to collect clinical and biological measures to develop an Artificial Intelligence based algorithm and clinical decision support tool to predict the 12-week response to adalimumab, a tumor necrosis factor receptor antagonist in adults with a clinical diagnosis of rheumatoid arthritis. 

The primary purpose of this study is to describe the utilization and findings on magnetic resonance imaging (MRI) of the hands and feet in patients with seronegative rheumatoid arthritis (RA) (based on the ACR 1987 or 2010 classification criteria) compared to the findings seen in patients with seropositive disease (RF or ACPA positive).

The purpose of this pilot study is to analyze the effectiveness of a new ultrasound microvessel imaging technology for evaluation of synovitis in patients with rheumatoid arthritis.

The purpose of this study is to establish a cohort of clinical and biological samples of patients with early rheumatoid arthritis or arthritis like undifferentiated inflammatory arthritis in order to address multiple critical barriers that exist to improved outcomes for patients with RA and other chronic inflammatory arthritides, including: (1) gaps in understanding disease mechanisms; (2) the lack of highly useful diagnostic and prognostic tools; and (3) the unavailability of personalized, targeted therapies for patients with early inflammatory arthritis.
 

The purpose of this study is to understand the extent of routine cardiovascular screening in patients with rheumatoid arthritis to improve management of their cardiovascular disease and optimize cardiovascular preventive strategies for this group of patients.

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.

The purpose of this study is to establish the immunometabolic profile of T cells isolated from patients with Rheumatoid Arthritis/Interstitial Lung Disease (RA/ILD), to identify distinguishing features in the metabolic status of T cells from RA patients with and without ILD, and to explore the use of immunometabolic determinants as a biomarker in RA patients with and without ILD.

The purpose of this study is to establish a comparator cohort of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other spondyloarthropathies. We will collect demographic information, historical information about diagnosis and past treatment, and clinical, radiographic, and laboratory data on each patient using standardized data collection forms.  We will also collect blood and synovial tissue samples from each patient.  This will provide data and material for clinical and translational research to address questions related to the fundamental differences between the spondyloarthropathies and inflammatory arthritis relating to the response of bone to chronic inflammation.  We intend to enroll sequential ...

The purpose of this study is to see if whole blood-based blood biomarker (i.e., cytokine) predicts status and severity of diseases such as asthma, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), or Inflammatory Bowel Disease (IBD).

The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including  systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.